Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Abstract Background Neuromyelitis optica (NMO) is a severe inflammatory autoimmune disorder of the central nervous system and often results in paralysis or blindness. Rituximab (RTX) is a mouse–human chimeric monoclonal antibody specific for the CD20 antigen on B lymphocytes and used to treat many a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-03-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12883-019-1261-2 |